A Multicenter, Phase III, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy Regimens in Subjects With Previously Untreated Metastatic Breast Cancer

Trial Profile

A Multicenter, Phase III, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy Regimens in Subjects With Previously Untreated Metastatic Breast Cancer

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Apr 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Capecitabine; Cyclophosphamide; Docetaxel; Doxorubicin; Epirubicin; Fluorouracil; Paclitaxel
  • Indications Advanced breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms RIBBON-1
  • Sponsors Genentech
  • Most Recent Events

    • 05 Apr 2016 Status changed from active, no longer recruiting to completed, according to European Clinical Trials Database record.
    • 09 Apr 2014 Results presented at the 105th Annual Meeting of the American Association for Cancer Research.
    • 26 Feb 2013 Planned End Date changed from 1 Jul 2008 to 1 Dec 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top